An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

NCT02911857 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Periodic Fevers Syndrome

Interventions

BIOLOGICAL: Canakinumab (AIN457)

Sponsor

Novartis Pharmaceuticals